Literature DB >> 1617231

Possible mechanisms of type I collagen-induced vascular tube formation.

C J Jackson1, K Jenkins, L Schrieber.   

Abstract

UNLABELLED: We investigated the effect of type I collagen on endothelial behaviour following its contact with the apical versus basal surface of cultured human endothelial cells. When endothelial cells were plated onto type I collagen they attached via their basal surface and formed a confluent monolayer. However, when type I collagen (100 micrograms/ml) was added directly to the growth medium, so that it made contact with the apical surface of endothelial cells, it induced rapid capillary-like tube formation. Possible mechanisms were assessed using a) polyclonal (anti-VLA-2) and monoclonal (AK7) antibodies to different epitopes on the alpha 2 beta 1 integrin receptor for collagen and b) drugs (chlorpromazine and trifluoperazine) that inhibit protein kinase C activity. Both anti-VLA-2 and AK7 (1-50 micrograms/ml) showed a dose-dependent inhibition of tube formation and cell attachment. At 50 micrograms/ml, anti-VLA-2 completely inhibited tube formation whereas AK7 caused only partial inhibition (less than 50%). By contrast, AK7 was a more potent inhibitor of cell attachment than anti-VLA-2. Both chlorpromazine and trifluoperazine prevented tube formation.
CONCLUSIONS: 1) The alpha 2 beta 1 integrin receptor plays a role in both endothelial cell attachment and the induction of tube formation by type I collagen. 2) Protein kinase C may be involved in collagen-induced tube formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617231     DOI: 10.1007/978-3-0348-7001-6_30

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  1 in total

Review 1.  Collagen induced MMP-2 activation in human breast cancer.

Authors:  E W Thompson; M Yu; J Bueno; L Jin; S N Maiti; F L Palao-Marco; H Pulyaeva; J W Tamborlane; R Tirgari; I Wapnir
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.